Boston Scientific Corporation $BSX Shares Sold by Peak Financial Management Inc.

Peak Financial Management Inc. decreased its position in shares of Boston Scientific Corporation (NYSE:BSX) by 14.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,945 shares of the medical equipment provider’s stock after selling 505 shares during the quarter. Peak Financial Management Inc.’s holdings in Boston Scientific were worth $316,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of BSX. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after acquiring an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after acquiring an additional 1,664,108 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Boston Scientific by 161.9% during the first quarter. Assenagon Asset Management S.A. now owns 2,485,696 shares of the medical equipment provider’s stock valued at $250,757,000 after acquiring an additional 1,536,663 shares during the period. Swedbank AB boosted its holdings in shares of Boston Scientific by 114.5% during the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after acquiring an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. lifted its holdings in Boston Scientific by 10.8% in the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock worth $1,426,779,000 after purchasing an additional 1,383,524 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on BSX shares. Wall Street Zen downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Raymond James Financial upped their price objective on shares of Boston Scientific from $121.00 to $124.00 and gave the stock a “strong-buy” rating in a report on Thursday, July 24th. Evercore ISI reduced their price objective on shares of Boston Scientific from $115.00 to $110.00 and set an “outperform” rating for the company in a report on Tuesday. UBS Group upped their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a “buy” rating in a report on Thursday, July 24th. Finally, Leerink Partnrs raised shares of Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $120.71.

Insider Activity

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total value of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at $222,646.19. This represents a 58.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares in the company, valued at $1,959,328.37. This represents a 17.79% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $96.73 on Thursday. The company has a 50-day moving average of $102.34 and a two-hundred day moving average of $101.96. The stock has a market cap of $143.33 billion, a price-to-earnings ratio of 57.58, a PEG ratio of 2.31 and a beta of 0.61. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. Boston Scientific Corporation has a one year low of $80.64 and a one year high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the prior year, the firm earned $0.62 EPS. The firm’s quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.